APBA3 and Borderline personality disorder: No case–control differences in APBA3 or MCF2 methylation were observed. However, among BPD patients undergoing DBT, those who responded to therapy had significantly higher baseline methylation of APBA3 and MCF2 than non-responders, suggesting these marks predicted treatment outcome.